242 related articles for article (PubMed ID: 28433470)
1. Daily supplementation of dietary protein improves the metabolic effects of GLP-1-based pharmacotherapy in lean and obese rats.
Mietlicki-Baase EG; Koch-Laskowski K; McGrath LE; Krawczyk J; Pham T; Lhamo R; Reiner DJ; Hayes MR
Physiol Behav; 2017 Aug; 177():122-128. PubMed ID: 28433470
[TBL] [Abstract][Full Text] [Related]
2. Intraduodenal milk protein concentrate augments the glycemic and food intake suppressive effects of DPP-IV inhibition.
Olivos DR; McGrath LE; Turner CA; Montaubin O; Mietlicki-Baase EG; Hayes MR
Am J Physiol Regul Integr Comp Physiol; 2014 Feb; 306(3):R157-63. PubMed ID: 24352410
[TBL] [Abstract][Full Text] [Related]
3. Glucagon-like peptide-1 response to whey protein is less diminished by dipeptidyl peptidase-4 in comparison with responses to dextrin, a lipid and casein in rats.
Shimizu Y; Hara H; Hira T
Br J Nutr; 2021 Feb; 125(4):398-407. PubMed ID: 32713353
[TBL] [Abstract][Full Text] [Related]
4. Hindbrain DPP-IV inhibition improves glycemic control and promotes negative energy balance.
Mietlicki-Baase EG; McGrath LE; Koch-Laskowski K; Krawczyk J; Pham T; Lhamo R; Reiner DJ; Hayes MR
Physiol Behav; 2017 May; 173():9-14. PubMed ID: 28119159
[TBL] [Abstract][Full Text] [Related]
5. Positive interplay between FFAR4/GPR120, DPP-IV inhibition and GLP-1 in beta cell proliferation and glucose homeostasis in obese high fat fed mice.
Owolabi AI; Corbett RC; Flatt PR; McKillop AM
Peptides; 2024 Jul; 177():171218. PubMed ID: 38621590
[TBL] [Abstract][Full Text] [Related]
6. Novel role of GLP-1 receptor signaling in energy expenditure during chronic high fat diet feeding in rats.
Krieger JP; Langhans W; Lee SJ
Physiol Behav; 2018 Aug; 192():194-199. PubMed ID: 29654813
[TBL] [Abstract][Full Text] [Related]
7. Clozapine and quetiapine acutely reduce glucagon-like peptide-1 production and increase glucagon release in obese rats: implications for glucose metabolism and food choice behaviour.
Smith GC; Vickers MH; Cognard E; Shepherd PR
Schizophr Res; 2009 Nov; 115(1):30-40. PubMed ID: 19679451
[TBL] [Abstract][Full Text] [Related]
8. Liraglutide suppression of caloric intake competes with the intake-promoting effects of a palatable cafeteria diet, but does not impact food or macronutrient selection.
Hyde KM; Blonde GD; le Roux CW; Spector AC
Physiol Behav; 2017 Aug; 177():4-12. PubMed ID: 28366815
[TBL] [Abstract][Full Text] [Related]
9. Effects of long-term dipeptidyl peptidase-IV inhibition on body composition and glucose tolerance in high fat diet-fed mice.
Liu X; Harada N; Yamane S; Kitajima L; Uchida S; Hamasaki A; Mukai E; Toyoda K; Yamada C; Yamada Y; Seino Y; Inagaki N
Life Sci; 2009 Jun; 84(25-26):876-81. PubMed ID: 19358859
[TBL] [Abstract][Full Text] [Related]
10. Effect of Sitagliptin on Islet Function in Pancreatic Insufficient Cystic Fibrosis With Abnormal Glucose Tolerance.
Kelly A; Sheikh S; Stefanovski D; Peleckis AJ; Nyirjesy SC; Eiel JN; Sidhaye A; Localio R; Gallop R; De Leon DD; Hadjiliadis D; Rubenstein RC; Rickels MR
J Clin Endocrinol Metab; 2021 Aug; 106(9):2617-2634. PubMed ID: 34406395
[TBL] [Abstract][Full Text] [Related]
11. Glucose-lowering effect of the DPP-4 inhibitor sitagliptin after glucose and non-glucose macronutrient ingestion in non-diabetic subjects.
Ohlsson L; Alsalim W; Carr RD; Tura A; Pacini G; Mari A; Ahrén B
Diabetes Obes Metab; 2013 Jun; 15(6):531-7. PubMed ID: 23331498
[TBL] [Abstract][Full Text] [Related]
12. Whey protein hydrolysates improve high-fat-diet-induced obesity by modulating the brain-peripheral axis of GLP-1 through inhibition of DPP-4 function in mice.
Rai C; Priyadarshini P
Eur J Nutr; 2023 Sep; 62(6):2489-2507. PubMed ID: 37154934
[TBL] [Abstract][Full Text] [Related]
13. Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice.
Waget A; Cabou C; Masseboeuf M; Cattan P; Armanet M; Karaca M; Castel J; Garret C; Payros G; Maida A; Sulpice T; Holst JJ; Drucker DJ; Magnan C; Burcelin R
Endocrinology; 2011 Aug; 152(8):3018-29. PubMed ID: 21673098
[TBL] [Abstract][Full Text] [Related]
14. Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner.
Hausenloy DJ; Whittington HJ; Wynne AM; Begum SS; Theodorou L; Riksen N; Mocanu MM; Yellon DM
Cardiovasc Diabetol; 2013 Oct; 12():154. PubMed ID: 24148218
[TBL] [Abstract][Full Text] [Related]
15. Effects of dipeptidyl peptidase IV inhibition on glycemic, gut hormone, triglyceride, energy expenditure, and energy intake responses to fat in healthy males.
Heruc GA; Horowitz M; Deacon CF; Feinle-Bisset C; Rayner CK; Luscombe-Marsh N; Little TJ
Am J Physiol Endocrinol Metab; 2014 Nov; 307(9):E830-7. PubMed ID: 25231186
[TBL] [Abstract][Full Text] [Related]
16. Feedback suppression of meal-induced glucagon-like peptide-1 (GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment.
Baranov O; Kahle M; Deacon CF; Holst JJ; Nauck MA
Diabetes Obes Metab; 2016 Nov; 18(11):1100-1109. PubMed ID: 27300579
[TBL] [Abstract][Full Text] [Related]
17. Anti-obesity effects of KR-66195, a synthetic DPP-IV inhibitor, in diet-induced obese mice and obese-diabetic ob/ob mice.
Lee EY; Kim YW; Oh H; Choi CS; Ahn JH; Lee BW; Kang ES; Cha BS; Lee HC
Metabolism; 2014 Jun; 63(6):793-9. PubMed ID: 24684824
[TBL] [Abstract][Full Text] [Related]
18. Continuous feeding of a combined high-fat and high-sucrose diet, rather than an individual high-fat or high-sucrose diet, rapidly enhances the glucagon-like peptide-1 secretory response to meal ingestion in diet-induced obese rats.
Pinyo J; Hira T; Hara H
Nutrition; 2019 Jun; 62():122-130. PubMed ID: 30878816
[TBL] [Abstract][Full Text] [Related]
19. In Vivo Inhibition of Dipeptidyl Peptidase 4 Allows Measurement of GLP-1 Secretion in Mice.
Smits MM; Galsgaard KD; Jepsen SL; Albrechtsen NW; Hartmann B; Holst JJ
Diabetes; 2024 May; 73(5):671-681. PubMed ID: 38295385
[TBL] [Abstract][Full Text] [Related]
20. Combined Amylin/GLP-1 pharmacotherapy to promote and sustain long-lasting weight loss.
Liberini CG; Koch-Laskowski K; Shaulson E; McGrath LE; Lipsky RK; Lhamo R; Ghidewon M; Ling T; Stein LM; Hayes MR
Sci Rep; 2019 Jun; 9(1):8447. PubMed ID: 31186439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
